Oncolytic Virus Therapy Trends and Forecast
The future of the global oncolytic virus therapy market looks promising with opportunities in the breast cancer, lung cancer, melanoma, ovarian cancer, and prostate cancer markets. The global oncolytic virus therapy market is expected to grow with a CAGR of 15.8% from 2024 to 2030. The major drivers for this market are growing rates of cancer among people worldwide, increasing awareness campaign to support immunotherapy, and rising advanced or treatment-resistant cancers.
• Lucintel forecasts that, within the virus type category, genetically engineered oncolytic virus is expected to witness a higher growth over the forecast period.
• Within the application category, breast cancer is expected to witness the highest growth over the forecast period.
• In terms of regions, North America is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report.
Emerging Trends in the Oncolytic Virus Therapy Market
The omitted area in the oncolytic virus therapy market is likely to create opportunities that will enhance cancer management practices in a new way.
• Combination Therapies: Incorporating enhanced efficiency of oncolytic viruses along with therapies such as immune checkpoint inhibitors and targeted therapies.
• Personalized Medicine: Implementation of specific CARTs against unique oncolytic viruses for the treatment of corresponding tumors and mutations.
• Advanced Delivery Systems: The field of biology has seen considerable advancements in delivery methods, which help to target oncolytic viruses more efficiently.
• Expanded Indications: Research into the effectiveness of oncolytic virus therapy for cancers beyond those traditionally treated.
• Regulatory Advancements: Ongoing improvements in regulatory pathways, including grants of breakthrough designations and fast-track approvals for therapies that have shown early promise.
Trends in the oncolytic virus therapy market include merging oncolytic viruses with other promising therapies, new approaches in virus delivery, expanded applications, enhanced cooperation, and increased adoption of innovative therapies aimed at improving the efficacy and accessibility of cancer treatment.
Recent Developments in the Oncolytic Virus Therapy Market
Recent developments in the oncolytic virus therapy market, including mergers and acquisitions, show noteworthy advancements.
• Clinical Trial Success: Safe and effective results of several oncolytic therapies in early-phase, mid-phase, and late-phase clinical trials have been completed successfully.
• Regulatory Approvals: Supportive regulations for breakthrough therapies and fast-tracking of oncolytic medical therapies by the FDA, EMA, and other regulatory stakeholders.
• Technological Improvements: Developments in the use of oncolytic viruses and genetic modifications to create more targeted and effective therapies.
• Manufacturing Capability: Growth in manufacturing facilities and capabilities for the clinical delivery of oncolytic virus therapy.
• Combination Strategies: Use of oncolytic virus therapy alongside other therapeutic approaches, such as chemotherapy, radiation, and immunotherapy.
• Global Research Initiatives: Increased global research initiatives and collaborations that enhance oncolytic treatment and information availability.
Recent developments in the oncolytic virus therapy market highlight clinical trial results, regulatory approvals, new techniques, manufacturing capabilities, combination strategies, and global collaborations, all indicating a progressive field with great potential in the fight against cancer.
Strategic Growth Opportunities for Oncolytic Virus Therapy Market
New application markets in oncolytic virus therapy are creating strategic growth opportunities.
• Cancer Type: Broadening the scope of oncolytic virus therapy to include various malignancies, including rare and untreatable variations.
• Combination Therapies: Exploring possible combinations with other treatment modalities, like immunotherapy and targeted therapies, to increase efficacy.
• Personalized Approaches: Development of personalized medicine approaches that tailor oncolytic virus treatment to specific oncoviruses and mutation profiles of patients.
• Emerging Markets: Venturing into emerging markets characterized by rising demand for advanced cancer treatments and favorable regulations.
• Technological Advancements: Incorporating state-of-the-art technologies such as gene editing systems and other advanced treatment methods.
• Collaborations and Partnerships: Working collaboratively with academia, biotech companies, and pharmaceutical firms for innovation and development.
Growth strategies in the oncolytic virus therapy market include multi-faceted cancer targeting, combination therapies, customization, geographical expansion of novel treatment options, technology advancement, and alliance development, all of which can be leveraged for market growth.
Oncolytic Virus Therapy Market Driver and Challenges
Several factors are driving the oncolytic virus therapy market, while many challenges remain.
The factors driving the oncolytic virus therapy market include:
• Innovation and Research: Rapid evolution in technological methods, such as viral engineering and oncolytic virus technologies, leading to new therapeutic solutions.
• Clinical Success: Positive responses to clinical trials of oncolytic virus therapies, demonstrating therapeutic efficacy and safety.
• Regulatory Support: Favorable regulations and expedited approval processes that shorten development and commercialization timelines.
• Growing Cancer Incidence: Increasing numbers of cancer patients create a rising need for effective new therapies.
• Investment and Funding: Significant investment from venture capital and pharmaceutical companies interested in research and development activities.
Challenges in the oncolytic virus therapy market include:
• Complex Manufacturing: Inherent limitations in production processes for oncolytic virus therapies, which can be expensive and labor-intensive.
• Regulatory Hurdles: Managing risks in compliance with diverse regulatory frameworks across different regions.
• Market Competition: Competition from other groundbreaking cancer therapies and treatment modalities.
• Patient Accessibility: Ensuring availability of oncolytic virus therapies for patients, especially in low-resource areas.
• Safety Concerns: Potential safety risks or adverse effects associated with oncolytic virus therapies based on previous studies.
The growth of the oncolytic virus therapy market is driven by innovation, positive clinical outcomes, favorable regulations, increasing cancer incidence, and funding. However, it faces challenges such as complex manufacturing, regulatory hurdles, competition, patient accessibility, and safety concerns that must be addressed for economic expansion.
List of Oncolytic Virus Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies oncolytic virus therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the oncolytic virus therapy companies profiled in this report include-
• Amunbio
• Astellas Pharma
• AstraZeneca
• BioInvent International
• Boehringer Ingelheim International
• Calidi Biotherapeutics
• Candel Therapeutics
• Daiichi Sankyo Company
• Elicera Therapeutics
• EpicentRx
Oncolytic Virus Therapy by Segment
The study includes a forecast for the global oncolytic virus therapy by virus type, application, end use, and region.
Oncolytic Virus Therapy Market by Virus Type [Analysis by Value from 2018 to 2030]:
• Genetically Engineered Oncolytic Viruses
• Oncolytic Wild-Type Viruses
Oncolytic Virus Therapy Market by Application [Analysis by Value from 2018 to 2030]:
• Breast Cancer
• Lung Cancer
• Melanoma
• Ovarian Cancer
• Prostate Cancer
• Others
Oncolytic Virus Therapy Market by End Use [Analysis by Value from 2018 to 2030]:
• Cancer Research Institutes
• Hospitals
• Specialty Clinics
• Others
Oncolytic Virus Therapy Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Oncolytic Virus Therapy Market
The growth strategies of major players in the market focus on expansion and strategic partnerships. Below is an overview of recent developments by key oncolytic virus therapy market players in key regions: USA, Indian, Chinese, and Japanese.
• USA: In the USA, recent news on theragnostics involving oncolytic viruses highlights the speed of clinical trials and expedited therapy approvals. Some oncolytic virus products developed by biopharma companies have received breakthrough therapy designations from the FDA, facilitating faster market entry. Advancements in therapies based on oncolytic adenoviruses, like Oncorine, and improvements in oncolytic virus and immune checkpoint combination therapies are notable. Additionally, there is growing interest and investment in developing patient-specific oncolytic virus therapies targeting specific tumor phenotypes.
• China: In Chinese, the oncolytic virus therapy market is relatively young but is attracting significant investments in research and development. Recent successes include the first oncolytic virus therapies that have shown positive results in early-phase clinical trials, indicating the promise of this novel cancer treatment. The Chinese government is fostering the growth of oncolytic virus therapies through supportive policies and sponsorships. Emphasis is placed on developing therapies using local oncolytic virus vectors, with increased collaboration from foreign firms to leverage expertise in this area.
• India: The Indian oncolytic virus therapy market is expanding due to domestic and foreign investments. Recent developments include early-phase clinical trials aimed at cost and availability considerations. Indian biotechnology companies are focusing on developing affordable oncolytic virus therapies suitable for mass production. Furthermore, collaborations between Indian institutions and multinational pharmaceutical companies are increasing to expedite the development and commercialization of oncolytic virus therapies.
• Japan: The oncolytic virus therapy market in Japan is advancing with a focus on research and clinical applications. Japanese pharmaceutical companies are actively developing and applying oncolytic viruses, often combining them with targeted therapies and immunotherapy. The Japanese government supports these initiatives through regulatory channels and promotes innovative treatments. Moreover, the focus on precision medicine involves developing and administering oncolytic viruses based on specific tumor genetic and molecular characteristics.
If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the growth forecast for oncolytic virus therapy market?
Answer: The global oncolytic virus therapy market is expected to grow with a CAGR of 15.8% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the oncolytic virus therapy market?
Answer: The major drivers for this market are growing rates of cancer among people worldwide, increasing awareness campaign to support immunotherapy, and rising advanced or treatment-resistant cancers.
Q3. What are the major segments for oncolytic virus therapy market?
Answer: The future of the oncolytic virus therapy market looks promising with opportunities in the breast cancer, lung cancer, melanoma, ovarian cancer, and prostate cancer markets.
Q4. Who are the key oncolytic virus therapy market companies?
Answer: Some of the key oncolytic virus therapy companies are as follows:
• Amunbio
• Astellas Pharma
• AstraZeneca
• BioInvent International
• Boehringer Ingelheim International
• Calidi Biotherapeutics
• Candel Therapeutics
• Daiichi Sankyo Company
• Elicera Therapeutics
• EpicentRx
Q5. Which oncolytic virus therapy market segment will be the largest in future?
Answer: Lucintel forecasts that genetically engineered oncolytic virus is expected to witness higher growth over the forecast period.
Q6. In oncolytic virus therapy market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period.
Q.7 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the oncolytic virus therapy market by virus type (genetically engineered oncolytic viruses and oncolytic wild-type viruses), application (breast cancer, lung cancer, melanoma, ovarian cancer, prostate cancer, and others), end use (cancer research institutes, hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Oncolytic Virus Therapy Market, Oncolytic Virus Therapy Market Size, Oncolytic Virus Therapy Market Growth, Oncolytic Virus Therapy Market Analysis, Oncolytic Virus Therapy Market Report, Oncolytic Virus Therapy Market Share, Oncolytic Virus Therapy Market Trends, Oncolytic Virus Therapy Market Forecast, Oncolytic Virus Therapy Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.